On February 25, 2021 Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, reported that it has received United States Patent No. 10,920,274 entitled "Nucleic Acid Coated Submicron Particles for Authentication" from the United States Patent and Trademark Office (Press release, Applied DNA Sciences, FEB 25, 2021, View Source [SID1234575685]). The newly issued patent strengthens the Company’s intellectual property position which includes 92 issued patents and 40 pending patent applications.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The claims of the issued patent cover methods of authenticating an object through the attachment and later authentication of submicron particles coated with a nucleic acid taggant. Claimed exemplary submicron particles include metal oxides, which encompass titanium dioxide and silicon dioxide that are commonly used as pharmaceutical and nutraceutical excipients for solid oral dosage forms and powdered formulations. In addition, submicron metal oxide particles are commonly used in the cosmetic industry.
"We are excited by our recent patent issuance, which we believe helps protect our CertainT platform and its Signature DNA molecular taggants as physical-chemical identifiers (PCID) for solid oral dosage forms and powders utilized in the pharmaceutical and nutraceutical markets," said Dr. James Hayward, President and CEO, Applied DNA. "While much of our recent focus has been on the biotherapeutic applications of our LinearDNATM platform, the global problem of counterfeit or adulterated pharmaceuticals and nutraceuticals has not gone away with the onset of the COVID-19 pandemic. We continue to pursue the implementation of the CertainT platform in the pharmaceutical and nutraceutical markets as an important business vertical with our industry partners."